A candidate FSHD therapy is moving into the clinic, and a patient organization helped put it there. It is the second time this has happened in three months.
On 24 September 2026, the U.S. Food and Drug Administration cleared an Investigational New Drug application for forazapadin in facioscapulohumeral muscular dystrophy. Alongside the clearance, Satellos Bioscience announced a partnership with the FSHD Canada Foundation, which will provide up to US$5 million in non-dilutive financing toward the drug’s clinical development in FSHD.
FSHD Canada Foundation is part of the Project Mercury country network and Global Task Force. We want to mark the milestone, and say something about why it matters beyond the headline.
What was announced
The clearance covers a planned Phase 2 randomized, double-blind, placebo-controlled proof-of-concept study in adults aged 18 and over living with FSHD, evaluating oral forazapadin at 60 mg and 120 mg. Satellos expects to initiate the study in the fourth quarter of 2026.
Forazapadin is an oral small-molecule inhibitor of AAK1, a protein Satellos associates with the body’s natural muscle repair and regeneration biology. The compound was previously referred to as SAT-3247 and is already in Phase 2 development in Duchenne muscular dystrophy; FSHD is its second clinical indication.
The FSHD Canada Foundation’s contribution takes the form of milestone payments over the next five quarters, in exchange for a capped revenue-sharing interest in future FSHD-related proceeds.
Twice in three months
In July 2026, the FSHD Canada Foundation announced a clinical development and licensing collaboration with NovMetaPharma, a Seoul-based company, to advance Cyclo-Z into FSHD. Cyclo-Z is an oral candidate designed to preserve and restore skeletal muscle, and the deal was structured the same way: funding for clinical development in exchange for a revenue-sharing interest tied to future FSHD-related proceeds, with the company retaining ownership and global rights. That agreement was reported at US$3.7 million.
Two deals in three months is no longer an experiment. It is a model: screen compounds, evaluate them rigorously, then put patient-raised capital behind the step companies find hardest to fund — the move from promising biology into a human trial.
Neither deal was done alone. NovMetaPharma’s announcement credits Solve FSHD, the FSHD Society and FSHD Global alongside FSHD Canada; FSHD Global has also publicly backed the Satellos program. Four organizations across three continents, all connected through the World FSHD Alliance and Project Mercury, standing behind two candidates that now have a route into the clinic.
This is the coordination argument in its most concrete form. Not a shared document or a joint statement but two financing deals that exist because organizations in Canada, the United States and Australia were willing to act on the same science together.
A patient organization as a financing partner
The detail worth pausing on is who is paying, and on what terms.
Non-dilutive financing from a patient foundation is not a grant to a laboratory and not a donation to a cause. It is capital placed directly into a clinical development program, structured with milestones and a return interest, by an organization that exists to serve patients rather than shareholders.
That adds something to what advocacy organizations do, rather than replacing any of it. Awareness and family support continue. So does funding academic research, and building registries and readiness infrastructure. Co-financing the route into human trials is a further layer on top, and it only works because the earlier ones are still being carried.
Each layer calls for its own capability: fundraising, scientific literacy, operational discipline, and now the ability to negotiate with a biotech on commercial terms. Organizations accumulate these; they do not trade one for the next.
Few national FSHD organizations could do on their own what FSHD Canada Foundation has now done twice. Few had to: both deals rest on support from partner organizations in other countries. That is the part other members of the Alliance should take from this, more than the deal terms themselves.
Where Project Mercury fits
Project Mercury did not develop forazapadin or Cyclo-Z, financed neither, and had no role in either agreement. What Project Mercury has been doing since 2023 is preparing the ground a study like this lands on.
The initiative was built bottom-up with partners across ten countries, FSHD Canada Foundation among them. Its purpose was to remove the practical barriers that cause rare disease trials to run late, recruit badly, or fail outright. Since 2023 the network has:
- Grown enrollment in FSHD patient registries past 10,000 participants
- Launched or expanded registries in six countries
- More than doubled the number of qualified clinical trial sites, from 25 in 2023 to 53 in 2025
- Published and disseminated a site onboarding and readiness toolkit
- Opened a workstream preparing health systems, clinicians and payers for the arrival of the first approved therapies
– Figures from the Project Mercury Interim Progress Report 2023–2025, published 11 May 2026.
A Phase 2 study opening in late 2026 will draw on exactly these things: identified and consented patients, sites that know how to run an FSHD protocol, and clinicians who can recognize and refer.
The work is not finished. Registry data set adoption typically takes three to four years, and registries across the rare disease field remain chronically under-resourced. Those are the gaps our Global Task Force is working through in the final phase to 2027.
Readiness cannot be built on demand
When a sponsor announces a trial, the community has roughly a year to respond. A registry cannot be built in that time. Nor can a site be qualified, a standard of care agreed, or a payer prepared for an evidence dossier.
This is the argument Project Mercury was created to test, and the reason its work is organized around shared assets rather than single-country projects. Readiness is either already in place when a program arrives, or it is not.
The corollary is uncomfortable: readiness is invisible when it works. No one writes a press release about the trial that recruited on schedule. That makes this kind of infrastructure persistently hard to fund, and persistently easy to let lapse once a project cycle ends.
What comes next
Project Mercury has completed its initial implementation and validation phase and runs through 2027. The question now in front of the Global Task Force is what happens to the assets afterwards.
The plan is to transfer them into the World FSHD Alliance as permanently stewarded, openly available infrastructure: the trial site toolkit, the registry guidance, the health technology assessment work, and the coordination model itself. A single institutional home means countries joining later do not have to rebuild what has already been built, and funders can see where their investment continues to live.
That transition was the central agenda item at our June in-person meeting and will be settled at the December meeting in Rome. We will report on it here as it takes shape.
Read more
Our congratulations go to the FSHD Canada Foundation and to Satellos Bioscience. We will be watching this next chapter closely.
The full announcement: Satellos Announces FDA Clearance of IND Application for Forazapadin in Facioscapulohumeral Muscular Dystrophy (FSHD) and a Partnership with FSHD Canada Foundation Providing Non-Dilutive Financing to Support Clinical Development, Satellos Bioscience Inc., 24 September 2026.
On the earlier collaboration: NovMetaPharma and the FSHD Canada Foundation Establish Collaboration to Advance Cyclo-Z, a First-in-Class Oral Muscle-Preserving Therapy, into Facioscapulohumeral Muscular Dystrophy, NovMetaPharma Co., Ltd., 6 July 2026.